Tackling metabolic disorders with non-coding RNAs

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.

The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Lead Program

RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.

We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.

Find out more

Meet Us At

Members of our management team will be at:

1st Annual BioPharma Obesity Innovation Forum 2025
January 11, San Francisco
JPM Healthcare Conference 2025
January 13-16, San Francisco

View all events

Corporate Factsheet

Download PDF